Elevance Health, Inc. (NYSE:ELV – Get Free Report) EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $432.14, for a total value of $3,205,182.38. Following the sale, the executive vice president now owns 8,423 shares of the company’s stock, valued at approximately $3,639,915.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Elevance Health Stock Performance
ELV stock opened at $430.76 on Friday. The firm has a market cap of $100.12 billion, a PE ratio of 16.28, a price-to-earnings-growth ratio of 1.08 and a beta of 0.82. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average price of $526.74 and a 200-day moving average price of $527.46. Elevance Health, Inc. has a 1-year low of $397.98 and a 1-year high of $567.26.
Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings results on Thursday, October 17th. The company reported $8.37 earnings per share for the quarter, missing analysts’ consensus estimates of $9.66 by ($1.29). Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The firm had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. During the same period last year, the company posted $8.99 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts expect that Elevance Health, Inc. will post 37.26 earnings per share for the current year.
Elevance Health Announces Dividend
Wall Street Analysts Forecast Growth
ELV has been the subject of a number of research reports. Stephens reissued an “underperform” rating on shares of Elevance Health in a report on Friday. Raymond James set a $485.00 target price on shares of Elevance Health in a research note on Friday. Cantor Fitzgerald cut their price objective on Elevance Health from $600.00 to $485.00 and set an “overweight” rating on the stock in a report on Friday. Barclays boosted their price target on Elevance Health from $611.00 to $622.00 and gave the stock an “overweight” rating in a report on Thursday, October 10th. Finally, Royal Bank of Canada decreased their price target on shares of Elevance Health from $585.00 to $478.00 and set an “outperform” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $572.27.
Get Our Latest Stock Analysis on ELV
Institutional Trading of Elevance Health
Hedge funds have recently bought and sold shares of the business. Bank & Trust Co bought a new stake in shares of Elevance Health during the 2nd quarter worth $27,000. Palisade Asset Management LLC bought a new stake in shares of Elevance Health in the 1st quarter worth approximately $28,000. Opal Wealth Advisors LLC bought a new position in Elevance Health during the second quarter worth about $28,000. Strategic Financial Concepts LLC purchased a new stake in shares of Elevance Health during the 2nd quarter valued at approximately $30,000. Finally, Register Financial Advisors LLC purchased a new stake in shares of Elevance Health during the 1st quarter valued at approximately $32,000. 89.24% of the stock is currently owned by institutional investors.
Elevance Health Company Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Articles
- Five stocks we like better than Elevance Health
- 3 Healthcare Dividend Stocks to Buy
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How to Calculate Options Profits
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What Are Dividends? Buy the Best Dividend Stocks
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.